NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Indivior Pharmaceuticals, Inc. (INDV) Stock Analysis

Indivior Pharmaceuticals, Inc. (INDV) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

INDV

$34.94

+$0.11 (+0.32%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare INDV with… →

INDV Key Statistics

As of Sep 4, 2026
Trading
Open
$34.74
Previous Close
$34.83
Day's Range
34.55–35.31
52-Week Range
22.22–42.81
Volume
1.02M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.11
Valuation
Market Cap
$4.12B
P/E Ratio
12.48
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
7.15
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.10
EPS (ttm)Profit attributable to each share over the last twelve months.
2.80
Financials (FY)
Revenue (FY)
$1.24B+4.29%
Net Income (FY)
$210.00M+2900.00%
Profit marginThe share of revenue left as profit after all costs and taxes.
26.75%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
118.03M
1-Year Return
+41.29%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
2.04M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

INDV Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−2.62%
2025+188.66%
2024−18.60%
2023−29.79%
2022+26.09%
2021+135.49%
2020+181.73%
2019−61.48%
2018−75.45%
2017+54.90%
2016 (partial year)−5.59%

As of September 4, 2026.

INDV Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.24B$210.00M16.9%
2024$1.19B$7.00M0.6%
2023$1.09B−$126.00M−11.5%
2022$901.00M−$44.00M−4.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.24B$993.00M$265.00M$210.00M16.9%
2024$1.19B$957.00M$234.00M$7.00M0.6%
2023$1.09B$919.00M$247.00M−$126.00M−11.5%
2022$901.00M$750.00M$215.00M−$44.00M−4.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

INDV Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricINDVDrug Manufacturers - Specialty & Generic medianvs median
P/E12.4819.2735% below
P/S ratio3.102.3035% above
Profit margin26.75%−3.14%29.9 pts above

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Indivior Pharmaceuticals, Inc. (INDV) at $4.12B. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 827.

Over the past 52 weeks the price has ranged from $22.22 to $42.81. INDV last closed at $34.94 on September 4, 2026. That is +$0.11 (+0.32%) against the previous close. The latest close sits 57.25% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $1.24B. Against the prior fiscal year total of $1.19B, that is a change of +4.29%. Net income for the same year was $210.00M. That is +2,900.00% against the prior fiscal year. Profit margin runs at 26.75%. That is 29.9 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are 2.8.

Across the 4 fiscal years on file, revenue moves from $901.00M in 2022 to $1.24B in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

INDV trades at a trailing price-to-earnings ratio of 12.48. That is 35.22% below the Drug Manufacturers - Specialty & Generic median of 19.27. On forward earnings the ratio is 7.15. The price-to-sales ratio is 3.1. On price-to-sales that is 34.93% above the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

Over the trailing twelve months the price has returned +41.29%. Across 10 years the annualized return works out at +5.00%. Beta against the wider market is reported at 1.11. Annualized volatility over the trailing 10 years is 197.01%.

Growth & Income

The record shows no dividend for INDV.

Across the complete calendar years on file, 2025 returned +188.66% and 2018 returned −75.45%. Of the 9 complete calendar years on file, 5 finished higher. 2026 is still running; the price is −2.62% year to date.

Peer Comparison

Indivior Pharmaceuticals, Inc. (INDV) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Indivior Pharmaceuticals, Inc. INDV $4.12B 12.5
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Indivior Pharmaceuticals, Inc. trades at a P/E of 12.5.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Indivior Pharmaceuticals, Inc.

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Visit website →